Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling
Roxanne Hastie, Fiona C Brownfoot, Ping Cannon, Nguyen Vi, Laura Tuohey, Natalie J Hannan, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
Placenta | W B SAUNDERS CO LTD | Published : 2019
OBJECTIVES: Preeclampsia is a hypertensive disorder of pregnancy with no available medical treatment. We recently reported sulfasalazine, an anti-inflammatory medication, to be a candidate therapeutic for preeclampsia. We showed sulfasalazine decreases placental secretion of soluble Fms-like tyrosine kinase-1 (sFlt-1), an anti-angiogenic factor strongly implicated in the pathogenesis of preeclampsia. However, the cellular mechanism(s) by which sulfasalazine reduces placental sFlt-1 are yet to be determined. Recently we also reported that both the mitochondria and the epidermal growth factor receptor (EGFR) signalling pathways regulate secretion of placental sFlt-1. In this study we sought to..View full abstract
Awarded by NHMRC Fellowships
Tong (#1136418), T.J. Kaitu'u-Lino (#1159261), N.J. Hannan (#1146128) and F. Brownfoot (#1142636) were supported by NHMRC Fellowships. The funders had no role in study design, data collection, analysis, decision to publish or the preparation of the manuscript.